Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Using Google Trends to investigate global COPD awareness.

Boehm A, Pizzini A, Sonnweber T, Loeffler-Ragg J, Lamina C, Weiss G, Tancevski I.

Eur Respir J. 2019 Aug 8;54(2). pii: 1901339. doi: 10.1183/13993003.01339-2019. Print 2019 Aug. No abstract available.

PMID:
31395673
2.

Assessing global COPD awareness with Google Trends.

Boehm A, Pizzini A, Sonnweber T, Loeffler-Ragg J, Lamina C, Weiss G, Tancevski I.

Eur Respir J. 2019 Jun 27;53(6). pii: 1900351. doi: 10.1183/13993003.00351-2019. Print 2019 Jun.

PMID:
31097517
3.

Clinical challenges in a patient with two BRAF V600E-mutated diseases.

Willenbacher E, Willenbacher W, Loeffler-Ragg J.

Thorax. 2019 Jun;74(6):620-622. doi: 10.1136/thoraxjnl-2018-212481. Epub 2019 Jan 19. No abstract available.

PMID:
30661020
4.

Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC).

Skvortsov S, Dudás J, Eichberger P, Witsch-Baumgartner M, Loeffler-Ragg J, Pritz C, Schartinger VH, Maier H, Hall J, Debbage P, Riechelmann H, Lukas P, Skvortsova I; EORTC PathoBiology Group.

Br J Cancer. 2014 May 27;110(11):2677-87. doi: 10.1038/bjc.2014.221. Epub 2014 May 1.

5.

Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy.

Gamerith G, Auer T, Amann A, Putzer D, Schenk B, Kircher B, Hilbe W, Zwierzina H, Loeffler-Ragg J.

Cancer Biol Ther. 2014 Mar 1;15(3):266-70. doi: 10.4161/cbt.27327. Epub 2013 Dec 18.

6.

Diagnostic and therapeutic challenges of a large pleural inflammatory myofibroblastic tumor.

Loeffler-Ragg J, Bodner J, Freund M, Steurer M, Uprimny C, Zelger B, Kähler CM.

Case Rep Pulmonol. 2012;2012:102196. doi: 10.1155/2012/102196. Epub 2012 Dec 31.

7.

AKR1B10 expression is associated with less aggressive hepatocellular carcinoma: a clinicopathological study of 168 cases.

Schmitz KJ, Sotiropoulos GC, Baba HA, Schmid KW, Müller D, Paul A, Auer T, Gamerith G, Loeffler-Ragg J.

Liver Int. 2011 Jul;31(6):810-6. doi: 10.1111/j.1478-3231.2011.02511.x. Epub 2011 Mar 29.

PMID:
21645211
8.

Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.

Zwierzina H, Bardelli A, Ciardiello F, Gariboldi M, Håkansson L, Lambrechts D, Lind GE, Loeffler-Ragg J, Schmoll H, Siena S, Tabernero J, Van Cutsem E.

Curr Opin Mol Ther. 2010 Dec;12(6):703-11. Review.

PMID:
21154162
9.

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.

Loeffler-Ragg J, Germing U, Sperr WR, Herrmann H, Zwierzina H, Valent P, Ulmer H, Stauder R.

Crit Rev Oncol Hematol. 2011 May;78(2):150-61. doi: 10.1016/j.critrevonc.2010.05.008. Epub 2010 Jun 26.

PMID:
20580567
10.

Identification of a 4.9-kilo base-pair Alu-mediated founder SDHD deletion in two extended paraganglioma families from Austria.

Janecke AR, Willett-Brozick JE, Karas C, Hasipek M, Loeffler-Ragg J, Baysal BE.

J Hum Genet. 2010 Mar;55(3):182-5. doi: 10.1038/jhg.2009.142. Epub 2010 Jan 29.

PMID:
20111059
11.

Proteomic identification of aldo-keto reductase AKR1B10 induction after treatment of colorectal cancer cells with the proteasome inhibitor bortezomib.

Loeffler-Ragg J, Mueller D, Gamerith G, Auer T, Skvortsov S, Sarg B, Skvortsova I, Schmitz KJ, Martin HJ, Krugmann J, Alakus H, Maser E, Menzel J, Hilbe W, Lindner H, Schmid KW, Zwierzina H.

Mol Cancer Ther. 2009 Jul;8(7):1995-2006. doi: 10.1158/1535-7163.MCT-08-0987. Epub 2009 Jun 30.

12.

EGFR inhibition as a therapy for head and neck squamous cell carcinoma.

Loeffler-Ragg J, Schwentner I, Sprinzl GM, Zwierzina H.

Expert Opin Investig Drugs. 2008 Oct;17(10):1517-31. doi: 10.1517/13543784.17.10.1517 . Review.

PMID:
18808311
13.

Identification of the rare EGFR mutation p.G796S as somatic and germline mutation in white patients with squamous cell carcinoma of the head and neck.

Schwentner I, Witsch-Baumgartner M, Sprinzl GM, Krugmann J, Tzankov A, Jank S, Zwierzina H, Loeffler-Ragg J.

Head Neck. 2008 Aug;30(8):1040-4. doi: 10.1002/hed.20831.

PMID:
18528899
14.

Infliximab therapy in pulmonary sarcoidosis.

Kähler CM, Heininger P, Loeffler-Ragg J, Vogelsinger H.

Am J Respir Crit Care Med. 2007 Aug 15;176(4):417; author reply 417-8. No abstract available.

PMID:
17675452
15.

Elevated levels of serum CD44 and E-cadherin predict an unfavourable outcome in myelodysplastic syndromes.

Loeffler-Ragg J, Steurer M, Ulmer H, Skvortsov S, Kircher B, Herold M, Zwierzina H, Stauder R.

Leukemia. 2006 Nov;20(11):2064-7. Epub 2006 Sep 7. No abstract available.

PMID:
16990777
16.

Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.

Auberger J, Loeffler-Ragg J, Wurzer W, Hilbe W.

Curr Cancer Drug Targets. 2006 Jun;6(4):271-94. Review.

PMID:
16848720
17.

Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma.

Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G, Zwierzina H.

Eur J Cancer. 2006 Jan;42(1):109-11. Epub 2005 Dec 1.

PMID:
16324836
18.

Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.

Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H.

Apoptosis. 2005 Oct;10(5):1175-86.

PMID:
16151650
19.

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia: final results of a randomized phase III study (06903) of the EORTC Leukemia Cooperative Group.

Zwierzina H, Suciu S, Loeffler-Ragg J, Neuwirtova R, Fenaux P, Beksac M, Harousseau J, Nuessler V, Cermak J, Solbu G, Willemze R, de Witte T, Amadori S; EORTC Leukemia Cooperative Group.

Leukemia. 2005 Nov;19(11):1929-33.

PMID:
16151466
20.

Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.

Loeffler-Ragg J, Skvortsov S, Sarg B, Skvortsova I, Witsch-Baumgartner M, Mueller D, Lindner H, Zwierzina H.

Eur J Cancer. 2005 Oct;41(15):2338-46. Epub 2005 Aug 22.

PMID:
16115757
21.

Different proteome pattern of epidermal growth factor receptor-positive colorectal cancer cell lines that are responsive and nonresponsive to C225 antibody treatment.

Skvortsov S, Sarg B, Loeffler-Ragg J, Skvortsova I, Lindner H, Werner Ott H, Lukas P, Illmensee K, Zwierzina H.

Mol Cancer Ther. 2004 Dec;3(12):1551-8.

Supplemental Content

Loading ...
Support Center